SOUTH SAN FRANCISCO, Calif., March 23, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced upcoming presentations featuring clinical and translational data from its SENTI-202 program at the 11th Annual Innate Killer Conference, taking place March 24–25, 2026 in San Diego, California. The presentations will include data from the ongo ...

Summary of Senti Biosciences Conference Call Company Overview - **Company**: Senti Biosciences - **Focus**: Development of logic gating and gene circuits for cell therapy, particularly in oncology [3][4] Core Industry Insights - **Oncology Drug Development Challenge**: The primary challenge is to kill cancer cells without harming healthy cells. Traditional therapies often struggle to find clean targets that minimize side effects [3][4] - **Logic Gates Concept**: Senti is innovating by using logic gates to enhance the specificity of cell therapies, allowing for the recognition and killing of cancer cells while protecting healthy cells [4][5] Key Product: SENTI-202 - **Target Indication**: Acute Myeloid Leukemia (AML) is identified as a significant area of unmet need due to the difficulty in finding clean targets for treatment [8][9] - **Mechanism**: SENTI-202 utilizes two CAR receptors: an activating CAR for cancer targets (CD33 and FLT3) and an inhibitory CAR to protect healthy hematopoietic stem cells via the VSIG2 target [9][10] - **Clinical Data**: - Phase 1 study showed a 42% complete response (CR) rate in relapsed refractory AML patients, with 100% of CR patients being minimal residual disease (MRD) negative and a median durability of 7.6 months [24][26] - Safety profile was consistent with NK cell therapies, primarily grade 1 or 2 events [24][34] Competitive Landscape - **Unmet Need in AML**: The median survival for relapsed refractory AML patients is approximately 5.3 months, with existing therapies showing low CR rates (12-20%) [26][27] - **Senti's Differentiation**: Senti's approach with validated targets (CD33 and FLT3) and the use of engineered NK cells is positioned as a potential best-in-class solution compared to existing NK therapies that have shown lower response rates [82][83] Regulatory and Development Plans - **RMAT Designation**: Senti has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, facilitating closer collaboration for clinical development [42] - **Next Steps**: Plans to initiate pivotal trials later this year, with a focus on expanding indications beyond AML to high-risk myelodysplastic syndromes (MDS) [65][66] Future Directions - **Solid Tumor Applications**: Senti is exploring the application of its technology in solid tumors and other modalities, indicating a broad potential for its logic gating technology [69][70] - **Investigator Interest**: There is significant interest from major AML centers to participate in upcoming trials, reflecting the high demand for effective treatments in this space [61][62] Additional Considerations - **Patient Population**: The trial is designed to include a broad range of patients, with a focus on those who can tolerate low-dose chemotherapy [49][51] - **Biomarker Selection**: Currently, patients must be CD33 positive to participate, but ongoing analyses will continue to refine this requirement [52][54] This summary encapsulates the key points discussed during the conference call, highlighting Senti Biosciences' innovative approach to addressing significant challenges in oncology, particularly in AML treatment.

Core Insights - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3] - The company will present at the Leerink Partners 2026 Global Healthcare Conference on March 9, 2026, at 2:20 PM ET [1] Company Overview - Senti Bio is dedicated to creating innovative cell and gene therapies for patients with incurable diseases, utilizing a synthetic biology platform to engineer Gene Circuits [3] - The Gene Circuits are designed to selectively target and kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing for control post-administration [3] - The company's pipeline includes cell therapies engineered with Gene Circuits aimed at addressing challenging liquid and solid tumor indications, with preclinical evidence supporting their efficacy in both NK and T cells [3] - Senti Bio is also exploring the application of Gene Circuits in other disease modalities beyond oncology through ongoing partnerships [3]

Senti Biosciences (NasdaqCM:SNTI) FY Conference March 02, 2026 03:10 PM ET Company ParticipantsEllen Horste - Equity Research AssociateKanya Rajangam - President, Head of Research and Development, and Chief Medical OfficerTimothy Lu - Co-Founder and CEOConference Call ParticipantsPhil Nadeau - Managing Director and Research AnalystNone - AnalystEllen HorsteAfternoon, welcome back to TD Cowen's 46th Annual Healthcare Conference. I'm Ellen Horste, TD Cowen Biotech Associate. On behalf of Phil Nadeau's team, I ...

Core Insights - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1] - The company will present its Gene Circuit technology, pipeline progress, and strategic priorities at the TD Cowen 46th Annual Health Care Conference on March 2, 2026 [1] Company Overview - Senti Bio is dedicated to creating new cell and gene therapies for patients with incurable diseases by leveraging a synthetic biology platform to engineer Gene Circuits [3] - The Gene Circuits are designed to specifically target and kill cancer cells while sparing healthy cells, increasing specificity to target tissues, and allowing for control even after administration [3] - The company's pipeline includes cell therapies engineered with Gene Circuits aimed at addressing challenging liquid and solid tumor indications, with preclinical evidence supporting their efficacy in both NK and T cells [3] - Senti Bio is also exploring the potential applications of Gene Circuits in other modalities and diseases beyond oncology through ongoing partnerships [3]

Core Insights - Senti Biosciences, Inc. is advancing its proprietary Gene Circuit platform for next-generation cell and gene therapies, participating in a Cell & Gene Live virtual event to discuss innovative cell therapy technologies [1][2][3] Company Overview - Senti Bio is a clinical-stage biotechnology company focused on developing cell and gene therapies for incurable diseases, utilizing synthetic biology to engineer Gene Circuits that enhance precision and control in targeting cancer cells while sparing healthy cells [6] Product Development - SENTI-202 is the first Logic Gated off-the-shelf CAR-NK cell therapy designed to target CD33 and/or FLT3 expressing hematologic malignancies, such as AML and myelodysplastic syndrome (MDS), while protecting healthy bone marrow cells [4] - The therapy includes an OR GATE for targeting cancer cells, a NOT GATE to protect healthy cells, and calibrated-release IL-15 to enhance cell persistence and activity [4] - Currently, Senti Bio is enrolling adult patients with relapsed/refractory CD33 and/or FLT3 expressing hematologic malignancies in a Phase 1 clinical trial for SENTI-202, which may become a first-in-class allogeneic treatment for AML/MDS patients [4] Regulatory Designations - The FDA has granted Orphan Drug Designation (ODD) and Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202 for treating relapsed/refractory hematologic malignancies, including AML [5]

Core Insights - Senti Biosciences, Inc. has completed enrollment in its Phase 1 clinical trial for SENTI-202, a first-in-class CAR NK cell therapy targeting CD33 and FLT3 in patients with relapsed or refractory acute myeloid leukemia (R/R AML) [1][2][3] - The clinical data presented at the ASH 2025 Annual Meeting showed deep, minimal residual disease (MRD)-negative, durable complete remissions and a favorable safety profile [1][2] - The company is planning to advance SENTI-202 into a pivotal study for R/R AML and is evaluating potential expansions to newly diagnosed AML and pediatric AML, with discussions with the FDA expected in the first half of 2026 [1][3] Company Overview - Senti Bio is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][8] - SENTI-202 is designed to selectively target and eliminate hematologic malignancies while sparing healthy bone marrow cells, featuring an OR GATE for activation and a NOT GATE for protection of healthy cells [5] - The therapy has received Regenerative Medicine Advanced Therapy (RMAT) designation, which may facilitate an expedited development and review process [1][6]

Core Insights - Senti Biosciences, Inc. has been selected to present at the Healthcare Conference Taipei 2026, showcasing its Gene Circuit technology platform and strategic priorities [1][2][3] Company Overview - Senti Bio is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][4] - The company aims to create therapies that precisely target and kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing control post-administration [4] Presentation Details - The presentation is scheduled for February 10, 2026, from 10:30 AM to 10:40 AM local time, and will last for eight minutes [2] - The focus will be on the Gene Circuit technology, pipeline progress, and opportunities for partnerships in investment, research and development, manufacturing, and clinical collaboration [2][3] Strategic Importance - The conference will gather global investors and strategic partners, providing a platform for Senti Bio to discuss potential collaborations aimed at advancing transformative therapeutic programs [3]

Core Insights - Senti Biosciences, Inc. announced participation in a Virtual Investor CEO Connect Segment, highlighting its advancements in cell and gene therapies using the Gene Circuit platform [2][3] Group 1: FDA Designation and Clinical Trials - The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to SENTI-202, a potential first-in-class CAR-NK investigational cell therapy for relapsed/refractory hematologic malignancies, including AML [3] - SENTI-202 previously received Orphan Drug Designation from the FDA in June [3] - New data from a multinational clinical trial involving 20 patients (18 with evaluable responses) for SENTI-202 was presented at the American Society of Hematology (ASH) Annual Meeting [3] Group 2: Company Overview and Technology - Senti Bio is focused on developing next-generation cell and gene therapies for incurable diseases, utilizing a synthetic biology platform to engineer Gene Circuits [4] - The Gene Circuits are designed to selectively kill cancer cells while sparing healthy cells, enhancing specificity to target tissues, and allowing for post-administration control [4] - The company's pipeline includes cell therapies targeting both liquid and solid tumors, with preclinical evidence supporting the efficacy of Gene Circuits in NK and T cells [4]

Core Insights - Senti Biosciences, Inc. is participating in the Biotech Showcase 2026, highlighting its focus on next-generation cell and gene therapies using its proprietary Gene Circuit platform [1][3] - The panel presentation titled "Engineering the Future: Advances in Cell and Gene Therapies" will take place on January 13, 2026, at 8:00 AM PST [2] Company Overview - Senti Bio is a clinical-stage biotechnology company dedicated to developing innovative cell and gene therapies for patients with incurable diseases [4] - The company utilizes a synthetic biology platform to engineer Gene Circuits aimed at precisely targeting and killing cancer cells while sparing healthy cells [4] - Senti Bio's pipeline includes cell therapies designed to address challenging liquid and solid tumor indications, with preclinical evidence supporting the efficacy of Gene Circuits in both NK and T cells [4] Industry Context - The Biotech Showcase serves as a significant investor and networking conference for biotechnology and life sciences companies, providing a platform for presenting to investors and pharmaceutical executives [3] - This event is recognized for setting the tone for the biotechnology sector in the upcoming year, featuring multiple tracks, plenary sessions, and networking opportunities [3]